5 results on '"Parati, Mara"'
Number of results to display per page
Search Results
2. One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study
- Author
-
Faverio, P, Luppi, F, Rebora, P, D'Andrea, G, Stainer, A, Busnelli, S, Catalano, M, Modafferi, G, Franco, G, Monzani, A, Galimberti, S, Scarpazza, P, Oggionni, E, Betti, M, Oggionni, T, De Giacomi, F, Bini, F, Bodini, B, Parati, M, Bilucaglia, L, Ceruti, P, Modina, D, Harari, S, Caminati, A, Intotero, M, Sergio, P, Monzillo, G, Leati, G, Borghesi, A, Zompatori, M, Corso, R, Valsecchi, M, Bellani, G, Foti, G, Pesci, A, Faverio, Paola, Luppi, Fabrizio, Rebora, Paola, D'Andrea, Gabriele, Stainer, Anna, Busnelli, Sara, Catalano, Martina, Modafferi, Giuseppe, Franco, Giovanni, Monzani, Anna, Galimberti, Stefania, Scarpazza, Paolo, Oggionni, Elisa, Betti, Monia, Oggionni, Tiberio, De Giacomi, Federica, Bini, Francesco, Bodini, Bruno Dino, Parati, Mara, Bilucaglia, Luca, Ceruti, Paolo, Modina, Denise, Harari, Sergio, Caminati, Antonella, Intotero, Marcello, Sergio, Pietro, Monzillo, Giuseppe, Leati, Giovanni, Borghesi, Andrea, Zompatori, Maurizio, Corso, Rocco, Valsecchi, Maria Grazia, Bellani, Giacomo, Foti, Giuseppe, Pesci, Alberto, Faverio, P, Luppi, F, Rebora, P, D'Andrea, G, Stainer, A, Busnelli, S, Catalano, M, Modafferi, G, Franco, G, Monzani, A, Galimberti, S, Scarpazza, P, Oggionni, E, Betti, M, Oggionni, T, De Giacomi, F, Bini, F, Bodini, B, Parati, M, Bilucaglia, L, Ceruti, P, Modina, D, Harari, S, Caminati, A, Intotero, M, Sergio, P, Monzillo, G, Leati, G, Borghesi, A, Zompatori, M, Corso, R, Valsecchi, M, Bellani, G, Foti, G, Pesci, A, Faverio, Paola, Luppi, Fabrizio, Rebora, Paola, D'Andrea, Gabriele, Stainer, Anna, Busnelli, Sara, Catalano, Martina, Modafferi, Giuseppe, Franco, Giovanni, Monzani, Anna, Galimberti, Stefania, Scarpazza, Paolo, Oggionni, Elisa, Betti, Monia, Oggionni, Tiberio, De Giacomi, Federica, Bini, Francesco, Bodini, Bruno Dino, Parati, Mara, Bilucaglia, Luca, Ceruti, Paolo, Modina, Denise, Harari, Sergio, Caminati, Antonella, Intotero, Marcello, Sergio, Pietro, Monzillo, Giuseppe, Leati, Giovanni, Borghesi, Andrea, Zompatori, Maurizio, Corso, Rocco, Valsecchi, Maria Grazia, Bellani, Giacomo, Foti, Giuseppe, and Pesci, Alberto
- Abstract
Background: Long-term pulmonary sequelae following hospitalization for SARS-CoV-2 pneumonia is largely unclear. The aim of this study was to identify and characterise pulmonary sequelae caused by SARS-CoV-2 pneumonia at 12-month from discharge. Methods: In this multicentre, prospective, observational study, patients hospitalised for SARS-CoV-2 pneumonia and without prior diagnosis of structural lung diseases were stratified by maximum ventilatory support (“oxygen only”, “continuous positive airway pressure (CPAP)” and “invasive mechanical ventilation (IMV)”) and followed up at 12 months from discharge. Pulmonary function tests and diffusion capacity for carbon monoxide (DLCO), 6 min walking test, high resolution CT (HRCT) scan, and modified Medical Research Council (mMRC) dyspnea scale were collected. Results: Out of 287 patients hospitalized with SARS-CoV-2 pneumonia and followed up at 1 year, DLCO impairment, mainly of mild entity and improved with respect to the 6-month follow-up, was observed more frequently in the “oxygen only” and “IMV” group (53% and 49% of patients, respectively), compared to 29% in the “CPAP” group. Abnormalities at chest HRCT were found in 46%, 65% and 80% of cases in the “oxygen only”, “CPAP” and “IMV” group, respectively. Non-fibrotic interstitial lung abnormalities, in particular reticulations and ground-glass attenuation, were the main finding, while honeycombing was found only in 1% of cases. Older patients and those requiring IMV were at higher risk of developing radiological pulmonary sequelae. Dyspnea evaluated through mMRC scale was reported by 35% of patients with no differences between groups, compared to 29% at 6-month follow-up. Conclusion: DLCO alteration and non-fibrotic interstitial lung abnormalities are common after 1 year from hospitalization due to SARS-CoV-2 pneumonia, particularly in older patients requiring higher ventilatory support. Studies with longer follow-ups are needed.
- Published
- 2022
3. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia
- Author
-
Salton, Francesco, primary, Confalonieri, Paola, additional, Meduri, G Umberto, additional, Santus, Pierachille, additional, Harari, Sergio, additional, Scala, Raffaele, additional, Lanini, Simone, additional, Vertui, Valentina, additional, Oggionni, Tiberio, additional, Caminati, Antonella, additional, Patruno, Vincenzo, additional, Tamburrini, Mario, additional, Scartabellati, Alessandro, additional, Parati, Mara, additional, Villani, Massimiliano, additional, Radovanovic, Dejan, additional, Tomassetti, Sara, additional, Ravaglia, Claudia, additional, Poletti, Venerino, additional, Vianello, Andrea, additional, Gaccione, Anna Talia, additional, Guidelli, Luca, additional, Raccanelli, Rita, additional, Lucernoni, Paolo, additional, Lacedonia, Donato, additional, Foschino Barbaro, Maria Pia, additional, Centanni, Stefano, additional, Mondoni, Michele, additional, Davì, Matteo, additional, Fantin, Alberto, additional, Cao, Xueyuan, additional, Torelli, Lucio, additional, Zucchetto, Antonella, additional, Montico, Marcella, additional, Casarin, Annalisa, additional, Romagnoli, Micaela, additional, Gasparini, Stefano, additional, Bonifazi, Martina, additional, D’Agaro, Pierlanfranco, additional, Marcello, Alessandro, additional, Licastro, Danilo, additional, Ruaro, Barbara, additional, Volpe, Maria Concetta, additional, Umberger, Reba, additional, and Confalonieri, Marco, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Le alleanze fra marche industriali e commerciali: un’indagine esplorativa sull’ingredient branding
- Author
-
Bertoli, Giuseppe, Busacca, Bruno Giuseppe, and Parati, Mara
- Subjects
INGREDIENT BRANDING ,BRAND ALLIANCES ,CO-BRANDING ,PRIVATE LABEL ,BRAND ALLIANCES, CO-BRANDING, INGREDIENT BRANDING, PRIVATE LABEL - Published
- 2015
5. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia
- Author
-
Martina Bonifazi, Donato Lacedonia, Anna Talia Gaccione, Luca Guidelli, Barbara Ruaro, Venerino Poletti, Claudia Ravaglia, Marco Confalonieri, Lucio Torelli, Paola Confalonieri, Massimiliano Villani, Alessandro Marcello, Sergio Harari, Francesco Salton, Maria Concetta Volpe, Matteo Davì, G. Umberto Meduri, Mario Tamburrini, Andrea Vianello, Annalisa Casarin, Danilo Licastro, Reba Umberger, Pierachille Santus, Raffaele Scala, Stefano Gasparini, Tiberio Oggionni, Antonella Zucchetto, Stefano Centanni, Maria Pia Foschino Barbaro, Rita Raccanelli, Mara Parati, Marcella Montico, Alberto Fantin, Pierlanfranco D'Agaro, Valentina Vertui, Xueyuan Cao, Dejan Radovanovic, Antonella Caminati, Vincenzo Patruno, Paolo Lucernoni, Alessandro Scartabellati, S. Tomassetti, Micaela Romagnoli, Simone Lanini, Michele Mondoni, Salton, Francesco, Confalonieri, Paola, Umberto Meduri, G, Santus, Pierachille, Harari, Sergio, Scala, Raffaele, Lanini, Simone, Vertui, Valentina, Oggionni, Tiberio, Caminati, Antonella, Patruno, Vincenzo, Tamburrini, Mario, Scartabellati, Alessandro, Parati, Mara, Villani, Massimiliano, Radovanovic, Dejan, Tomassetti, Sara, Ravaglia, Claudia, Poletti, Venerino, Vianello, Andrea, Talia Gaccione, Anna, Guidelli, Luca, Raccanelli, Rita, Lucernoni, Paolo, Lacedonia, Donato, Pia Foschino Barbaro, Maria, Centanni, Stefano, Mondoni, Michele, Davì, Matteo, Fantin, Alberto, Cao, Xueyuan, Torelli, Lucio, Zucchetto, Antonella, Montico, Marcella, Casarin, Annalisa, Romagnoli, Micaela, Gasparini, Stefano, Bonifazi, Martina, D'Agaro, Pierlanfranco, Marcello, Alessandro, Licastro, Danilo, Ruaro, Barbara, Volpe, MARIA CONCETTA, Umberger, Reba, and Confalonieri, Marco
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Methylprednisolone ,Major Articles ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,pneumonia ,Intubation ,SARS-cov-2 ,030212 general & internal medicine ,Mechanical ventilation ,SARS-CoV-2 ,business.industry ,ARDS ,COVID-19 ,Pneumonia ,Hazard ratio ,methylprednisolone ,medicine.disease ,Intensive care unit ,Confidence interval ,Clinical trial ,AcademicSubjects/MED00290 ,030104 developmental biology ,Infectious Diseases ,Oncology ,Anesthesia ,business ,medicine.drug - Abstract
Background In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality. Methods We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels. Results Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24–0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12–0.73) and more days off invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the 2 groups (P = .84). Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. Clinical trial registration. ClinicalTrials.gov NCT04323592., This multicenter observational study gave the first evidence that prolonged, low-dose methylprednisolone treatment is associated with a significantly lower hazard of death, reduced ICU burden and decreased ventilator dependence without affecting viral clearance in patients with severe COVID-19 pneumonia/ARDS.
- Published
- 2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.